Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
VREOF · OTC · United States · Pharmaceutical Preparations
In shortVireo Growth Inc. is loss-making, burns cash and holds more cash than debt, with revenue growing (+170.4% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -0.4% | 15/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -25.3% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -37.5% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -0.3% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.59× | 66/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.03× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 0.34 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -9.2% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 68.2% | 0/100 |
| Operating margin volatility | 20.8% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 53.3% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
1 older year available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 54 | 75 | 88 | 99 | 269 |
| Cost of revenue | 32 | 39 | – | – | – |
| Gross profit | 20 | 31 | 44 | 51 | 127 |
| Selling, general & admin | 34 | 34 | 28 | 28 | 81 |
| Operating income | (20) | (6.9) | 11 | 14 | (1) |
| Interest expense | 11 | 23 | 31 | 31 | – |
| Pre-tax income | (30) | (37) | (18) | (17) | (40) |
| Income tax | 4.1 | 5.9 | 7.7 | 11 | 28 |
| Net income | (34) | (42) | (26) | (28) | (68) |
| Diluted EPS | −$0.27 | −$0.33 | −$0.19 | −$0.16 | −$0.09 |
| Diluted shares (millions) | 124 | 128 | 135 | 180 | 735 |
1 older year available with the 10-year history. Essential plan, from €8.25/month →
0.34 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 14, 2026